ResMed is still a buy

Article Excerpt

RESMED INC., $224.30, is a buy. The company (New York symbol RMD; TSINetwork Rating: Average) (www.resmed.com; Shares outstanding: 146.9 million; Market cap: $33.0 billion; Dividend yield: 1.0%) fell in June 2024 from around $215 to as low as $180. The stock dropped after drugmaker Eli Lilly said that its weight-loss drug Zepbound sharply reduced the restriction, or blocking, of air flow in patients with obesity and obstructive sleep apnea (interrupted breathing during sleep). In our June 28, 2024, hotline, we wrote that the threat was overblown, and, that all things considered, ResMed’s outlook remains positive. In short, while there is a risk that a portion of obese CPAP patients will give up the device after losing weight on Zepbound, most patients taking weight-loss drugs will likely still need CPAP to control their sleep apnea. Note—the stock has since recovered all of the drop and moved even higher. ResMed is still a buy. buy…